Breast cancer risk not only was not associated with CYP17/A2 allele but also was related to A1 allele

Archives of Medical Science

Volumn 5, Issue 1, 2009, Pages 103-106

  Hosseini, Mojgan ^a   Houshmand, Massoud ^b,c   Ebrahimi, Ahmad ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^c Special Medical Centre   (Iran)

Author keywords

Breast cancer; CYP17 gene; MSPA1; PCR RFLP; Polymorphism; Susceptibility factor

Indexed keywords

CYTOCHROME P450 17; CYTOSINE; RESTRICTION ENDONUCLEASE; THYMINE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

EID: 65549169529     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17, 20 lyase): similarity with the gene for P450c21. DNA 1987; 6: 439-48.
2. Ambrosone CB, Moysich KB, Furberg H, et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003; 5: R45-51.
3. Mousavi SM, Montazeri A, Mohagheghi MA, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13: 383-91.
4. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: Results of a multi-center study. Asian Pac J Cancer Prev 2004; 5: 24-7.
5. Verla-Tebit E, Wang-Gohrke S, Chang-Claude J. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based patient - control study. Breast Cancer Res 2005; 7: R455-64.
6. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873-6.
7. Silva SN, Cabral MN, Bezerra de Castro G, et al. Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed. Oncol Rep 2006; 16: 781-8.
8. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 2000; 36: 2375-9.
9. Warren R, Skinner J, Sala E, et al. Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15: 1502-8.
10. Yanase T. 17 alpha-hydroxylase/17, 20-lyase defects. J Steroid Biochem Mol Biol 1995; 53: 153-7.
11. Franks S, White D, Gilling-Smith C, Carey A, Waterworth D, Williamson R. Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha. Baillieres Clin Endocrinol Metab 1996; 10: 193-203.
12. Crocitto LE, Feigelson HS, Yu MC, et al. Short report on DNA marker at candidate locus: a polymorphism in intron 6 of the CYP17 gene. Clin Genet 1997; 52: 68-9.
13. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997; 57: 1063-5.
14. Artamonov VV, Liubchenko LN, Shabanov MA, Babenko OV, Nemtsova MV, Zaletaev DV. Association of polymorphism of genetic markers of CYP19 and CYP17 with sporadic breast cancer [Russian]. Mol Biol 2003; 37: 975-82.
15. Bergman-Jungeström M, Gentile M, Lundin AC, Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 1999; 84: 350-3.
16. Spurdle AB, Hopper JL, Dite GS, et al. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2000; 92: 1674-81
17. Hamajima N, Iwata H, Obata Y, et al. No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 2000; 91: 880-5.
18. Mitrunen K, Jourenkova N, Kataja V, et al. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 1343-8.
19. Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC. HSD17B1 and CYP17 polymorphism and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003; 104: 450-7.
20. Spurdle AB, Hopper JL, Dite GS, et al. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2000; 92: 1674-81.
21. Dunning AM, Healey CS, Pharoah PD, et al. No association between a polymorphism in the steroid metabolism gene CYP17 and the risk of breast cancer. Br J Cancer 1998; 77: 2045-7.
22. Einarsdóttir K, Rylander-Rudqvist T, Humphreys K, et al. CYP17 gene polymorphism in relation to breast cancer risk: a Patient-control study. Breast Cancer Res 2005; 7: 890-6.
23. Hsieh YY, Tsai FJ, Chang CC, et al. Cytochrome P450c17alpha (CYP17) gene polymorphism is not associated with leiomyoma susceptibility. Genet Mol Biol 2002; 25: 361-4.
24. Han DF, Zhou X, Hu MB, et al. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J 2005; 118: 1507-16.
25. Chang JH, Gertig DM, Chen X, et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res 2005; 7: R513-21.